A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trial.
Stephan Thurau, Christoph M E Deuter, Arnd Heiligenhaus...
https://pubmed.ncbi.nlm.nih.gov/36325389/Actively Recruiting
Led by Kiora Pharmaceuticals, Inc. · Updated on 2026-09-09
28
Participants Needed
6
Research Sites
4 weeks
Total Duration
Researchers are evaluating the safety, tolerability, and effectiveness of KIO-104, an investigational drug given by injection into the eye, for adults with macular edema. This open-label, Phase 2 study aims to assess KIO-104 in participants diagnosed with macular edema caused by conditions such as non-infectious uveitis, retinal vein occlusion, diabetic retinopathy, or cataract surgery. The study is sponsored by Kiora Pharmaceuticals, Inc. and involves multiple treatment groups to explore different doses and dosing schedules. The study consists of two parts. Part A tests up to three doses of KIO-104 given every two weeks in two dose levels low and high. Part B evaluates up to three doses of KIO-104 selected from Part A at either two-week or four-week intervals. Participants receive the drug directly into the study eye via intravitreal injection according to their assigned dose and schedule. The study groups include low-dose and high-dose KIO-104 given every two weeks and low- or high-dose given every four weeks. Participants will attend study visits during treatment to receive injections and complete assessments. Researchers will measure safety and tolerability over about 23 months. Evaluations include eye exams, visual acuity tests, and imaging to assess macular thickness. Participants must follow study instructions, avoid certain medications, and adhere to contraception requirements. The total participation time spans screening through the treatment and follow-up periods, with close monitoring of outcomes and any side effects.
CONDITIONS
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
C
Claudia Gregorio-King
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Kiora Pharmaceuticals, Inc.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 6 to 12 weeks
Participants receive up to three intravitreal injections of KIO-104 in the study eye at assigned doses and schedules, either every 2 weeks or every 4 weeks.
Visits every 2 or 4 weeks for injections and assessments
Duration - Up to 23 months
Participants are monitored for safety, tolerability, and efficacy after completing treatment, including eye exams and imaging assessments.
Regular visits for safety and efficacy evaluations
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Stephan Thurau, Christoph M E Deuter, Arnd Heiligenhaus...
https://pubmed.ncbi.nlm.nih.gov/36325389/Kiora Pharmaceuticals, Inc.
Lead Sponsor